Zalecenia Postępowania Diagnostyczno-Terapeutycznego W Raku Nerkowokomórkowym

Wysocki, Piotr J.; Chłosta, Piotr; Chrzan, Robert; Czech, Anna; Gronostaj, Katarzyna; Konopka, Kamil; Krzakowski, Maciej; Kucharz, Jakub; Małecki, Krzysztof; Przydacz, Mikołaj; Tomczak, Piotr; Wiechno, Paweł; Żołnierek, Jakub

doi:10.5603/ocp.2020.0029

Cited by 4 publications

(5 citation statements)

References 161 publications

(191 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Green suggests a relative treatment benefit (light green a nonsignificant benefit, and dark green a significant benefit). Red suggests a relative treatment harm (light red a nonsignificant harm, and dark red a significant harm (Wysocki et al, 2020). Current treatment of mRCC is sequential, thus, combination therapy used early on in first-line therapy of favorable risk patients could affect subsequent management options.…”

Section: Figurementioning

confidence: 99%

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma—A network meta-analysis. Focus on cabozantinib combined with nivolumab

Niewada

Macioch

Konarska³

et al. 2023

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

Introduction: The combination of immunotherapy and targeted therapy is currently marking a new era in the treatment of renal cancer. The latest clinical guidelines recommend the use of drug combinations for the first-line treatment of advanced renal cancer. The aim of this review is to compare the efficacy of combined cabozantinib + nivolumab therapy with other immune checkpoint inhibitors combined with tyrosine kinase inhibitors or monoclonal antibodies blocking the CTLA-4 (cytotoxic T cell antigen 4) in the first-line treatment of metastatic clear-cell renal cell carcinoma (RCC).Methodology: A systematic literature search was carried out in the PubMed and EMBASE databases. Randomized controlled trials (RCTs) on therapies recommended by the latest EAU and ESMO guidelines for treatment-naïve metastatic RCC (i.e., lenvatinib + pembrolizumab, axitinib + pembrolizumab and nivolumab + ipilimumab) were searched. A network meta-analysis (NMA) was performed for data synthesis. The methodology of included RCTs was assessed using the Cochrane RoB two tool. The data were analyzed in the overall population as well as in risk subgroups defined according to the International Metastatic Database Consortium (IMDC) i.e., patients with a favorable and intermediate or poor prognoses. The most recent cut-off dates from included studies were analyzed.Results: Four RCTs (CheckMate 9 ER, KEYNOTE-426, CLEAR and CheckMate 214) were included in the review. No studies directly comparing cabozantinib + nivolumab with any of the drug combinations included in this review were available. NMA showed that cabozantinib + nivolumab was superior compared to axitinib + pembrolizumab and nivolumab + ipilimumab in all analyzed comparisons (overall population and IMDC risk subgroups), both in terms of overall survival and progression-free survival (PFS). The advantage of cabozantinib + nivolumab was statistically significant only for PFS when compared to nivolumab + ipilimumab in the overall population. The results for the comparison of cabozantinib + nivolumab with lenvatinib + pembrolizumab showed numerical superiority of lenvatinib + pembrolizumab combination in terms of overall survival, but none of the results were statistically significant. The advantage of lenvatinib + pembrolizumab over cabozantinib + nivolumab in terms of PFS was statistically significant in the overall and favorable prognosis population.Conclusion: Inclusion of the most recent cut-off data from CheckMate 9 ER did not affect the role of the cabozantinib + nivolumab combination for treatment-naïve metastatic RCC. Cabozantinib + nivolumab is an effective therapeutic option for the first-line treatment of advanced renal cancer that is recommended both in the latest European and American guidelines for all IMDC risk groups.

show abstract

Section: Figurementioning

confidence: 99%

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma—A network meta-analysis. Focus on cabozantinib combined with nivolumab

Niewada

Macioch

Konarska³

et al. 2023

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…There is a high burden of genitourinary cancers in Poland [18,19]. Prostate cancer is the most common cancer in men, accounting for 20.6% of all cancer cases in men [18].…”

Section: Introductionmentioning

confidence: 99%

“…Bladder cancer is the fourth most common cancer in men [18]. Kidney cancer accounts for 5% of cancer in men and 3% in women [19]. Moreover, in Poland, the prevalence of genitourinary cancer risk factors, such as smoking [10] and obesity [20] is high.…”

Section: Introductionmentioning

confidence: 99%

Awareness of Genitourinary Cancers Risk Factors—A 2024 Population-Based Cross-Sectional Study in Poland

Moczeniat,

Jankowski,

Duda-Zalewska

et al. 2024

Int J Public Health

View full text Add to dashboard Cite

ObjectiveThis study aimed to assess the awareness of genitourinary cancers risk factors among adults in Poland and to identify factors associated with public awareness of risk factors for genitourinary cancers.MethodsThis cross-sectional survey was carried out between 1 and 4 March 2024 in a nationwide sample of 2,165 adults in Poland. Quota sampling was used. Data were collected using computer-assisted web interview (CAWI) method.ResultsRegardless of the type of cancer (kidney, bladder, or prostate cancer), a family history of cancer was the most recognized risk factor indicated by over half of respondents. Over one-third were aware that chemical exposure increases the risk for bladder cancer (39.4%) or prostate cancer (34.2%). Smoking was recognized as a risk factor for kidney cancer by 40.6% of respondents. Female gender, having higher education, being occupationally active and the presence of chronic diseases were the most important factors (p < 0.05) associated with a higher level of awareness of genitourinary cancers risk factors.ConclusionThis study revealed gaps in public awareness of genitourinary cancers risk factors among adults in Poland, especially lifestyle-related and workplace-related risk factors.

show abstract

“…According to the current guidelines, not all RCC patients diagnosed with distant metastases require immediate initiation of systemic treatment and may undergo long-term active surveillance. Additionally, in the case of asymptomatic, oligometastatic disease, local therapeutic approaches (metastasectomy or stereotactic radiotherapy) represent the treatment of choice [3,4]. Some authors emphasize that complete resection of metastases in mRCC patients in combination with targeted therapy is correlated with longer OS compared to targeted therapy alone [5].…”

Section: Introductionmentioning

confidence: 99%

Do solitary pancreatic metastases of renal-cell carcinoma indicate an indolent disease with a strong indication for aggressive local treatment? A case report with literature review

Dobrzańska,

Potocki,

Wysocki

2024

Oncol Clin Pract

View full text Add to dashboard Cite

Renal-cell carcinoma (RCC) most often metastasizes to the lungs, liver, and brain. Metastases of RCC to the pancreas are very rare. In the last decade, only a few cases of metachronous metastasis of kidney cancer to the pancreas have been reported in the literature. This article presents a case report of a 75-year-old female patient with a 16-year history of treatment of clear-cell carcinoma of the kidney, in whom pancreatic metastases were detected twice. Renal-cell carcinoma may have an indolent course with late relapse or may show dissemination. It is important to establish new recommendations for long-term follow-up in patients after radical treatment.

show abstract

Zalecenia Postępowania Diagnostyczno-Terapeutycznego W Raku Nerkowokomórkowym

Abstract: Table of contents 1. Evidence-based guidelines for the management ..

Cited by 4 publications

References 161 publications

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma—A network meta-analysis. Focus on cabozantinib combined with nivolumab

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma—A network meta-analysis. Focus on cabozantinib combined with nivolumab

Awareness of Genitourinary Cancers Risk Factors—A 2024 Population-Based Cross-Sectional Study in Poland

Do solitary pancreatic metastases of renal-cell carcinoma indicate an indolent disease with a strong indication for aggressive local treatment? A case report with literature review

Contact Info

Product

Resources

About